Keros Therapeutics (KROS) to Release Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $3.6620 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $15.71 on Tuesday. The stock has a market capitalization of $478.68 million, a price-to-earnings ratio of 10.20 and a beta of 0.86. The stock’s 50 day moving average price is $18.74 and its two-hundred day moving average price is $17.09. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $22.55.

Institutional Trading of Keros Therapeutics

Several large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the last quarter. XTX Topco Ltd acquired a new stake in Keros Therapeutics in the fourth quarter valued at approximately $212,000. New York State Common Retirement Fund grew its stake in shares of Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after buying an additional 7,700 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Keros Therapeutics during the third quarter worth $176,000. Finally, Virtus Investment Advisers LLC increased its holdings in shares of Keros Therapeutics by 48.2% during the fourth quarter. Virtus Investment Advisers LLC now owns 12,367 shares of the company’s stock worth $252,000 after buying an additional 4,025 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Wall Street Analysts Forecast Growth

KROS has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Zacks Research lowered Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Wedbush lifted their target price on Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Wells Fargo & Company decreased their target price on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, Bank of America raised their price target on Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, November 28th. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $22.29.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.